Mecwins has been granted with more than 1.4M€ to develop ultrasensitive optoplasmonic immunoassays for the early detection of breast cancer under the Líneas Estratégicas Program
Mecwins, in collaboration with the Bionanomechanics Lab from [...]
Developing ‘Highly Sensitive’ Plasmonic Testing Tech
Mecwins Developing 'Highly Sensitive' Plasmonic Testing Tech for Laboratories, Point [...]
€4 million injection to help boost Mecwins’s position on the early diagnosis market
Mecwins has signed a financial agreement with its investor [...]
Mecwins Announces Strategic Partnership to Develop a Next Generation Platform for Point of Care (POC) Testing
This licensing and co-development agreement leverages Mecwins’ ultrasensitive AVAC [...]
Mecwins signs a R&D agreement with IRYCIS
Óscar Ahumada, PhD, CEO of Mecwins, has recently [...]
Our scientific promoter Prof. Javier Tamayo ranked among the top 2% most-cited researchers in the world
Our scientific promoter Prof. Javier Tamayo, leader of the Bionanomechanics Lab [...]
Mecwins continues to sponsor “Club Triatlón Canto Blanco”
Mecwins is still one of the proud sponsors of [...]
Mecwins’ scientist, Dr. Teresa Ramón, was granted with the Extraordinary Doctoral Thesis Award from the University of Granada
Dr. Teresa Ramon, our dear Senior Scientist from the Biosciences [...]
Our scientific advisor, Dr. Priscila Kosaka, was awarded for her research in the oncology field
Our scientific advisor, Dr. Priscila Kosaka, was awarded by Fundación [...]
Mecwins IVD4Sepsis project has been selected for publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website
Mecwins IVD4Sepsis project has been selected for publication in the [...]
